Esperion Therapeutics, Inc. Net Income Loss

• Esperion Therapeutics, Inc. showed an increase of +56.2% in Net Income Loss from 2024 to 2025.
• This data is from Esperion Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
• XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 15 years of available data (2011 to 2025), Esperion Therapeutics, Inc.'s Net Income Loss has declined by 109.7%.
• Historical annual values: Fiscal year 2025: -$22.68 million | Fiscal year 2024: -$51.75 million | Fiscal year 2023: -$209.25 million | Fiscal year 2022: -$233.66 million | Fiscal year 2021: -$269.11 million | Fiscal year 2020: -$143.55 million | Fiscal year 2019: -$97.17 million | Fiscal year 2018: -$201.81 million | Fiscal year 2017: -$166.99 million | Fiscal year 2016: -$74.98 million | Fiscal year 2015: -$49.78 million | Fiscal year 2014: -$36.38 million | Fiscal year 2013: -$26.09 million | Fiscal year 2012: -$11.74 million | Fiscal year 2011: -$10.82 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026